InvestorsHub Logo
Followers 53
Posts 1777
Boards Moderated 0
Alias Born 03/22/2015

Re: imanjen13 post# 370782

Thursday, 06/30/2022 1:31:10 PM

Thursday, June 30, 2022 1:31:10 PM

Post# of 401773

What amazes me is that our feckless leader doesn't have the balls to just call Lannett and ask the CEO what is there plan and timeline viz a viz the Adderall products.





I suspect those conversations have taken place, based on the two recent developments: 1) Addition of Sabril to the marketing agreement, and 2) Lannett moving Adderall ER to the discontinued list.

It didn't benefit Lannett very much to put the ANDA on the discontinued list. They can still activate the ANDA when they choose, but they will have to go through a substantial, costly, time-consuming process which is not much different than getting the approval in the first place. They would need to redo all the API certifications and commercial batches and then get a re-approval from FDA. They would not have discontinued it if they had any intention of commercializing it any time in the near future (several years for sure). I believe moving Adderall ER to the discontinued list was a small but significant show of commitment to ELTP, and likewise, Nasrat adding Sabril to the agreement is a show of his confidence in the stability of the Lannett deal.

.

#FreeSequestOx
#FreeTacoForShareholders

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News